genOway
Designs and develops genetically modified preclinical models for research.
ALGEN | PA
Overview
Corporate Details
- ISIN(s):
- FR0004053510
- LEI:
- 969500HMHUPR3KYXUT19
- Country:
- France
- Address:
- 31 RUE SAINT JEAN DE DIEU, 69007 LYON
- Website:
- https://www.genoway.com
Description
genOway is a biotechnology company that specializes in designing and developing genetically modified preclinical models. It provides biopharmaceutical companies and academic researchers with genetically engineered mouse, rat, and cell line models intended to improve the predictability of preclinical research. The company's portfolio includes a catalog of off-the-shelf models as well as customized model creation services. Key areas of application for its models include immuno-oncology and pharmacokinetic (PK) analysis, featuring a range of humanized models. genOway emphasizes a collaborative approach, providing scientifically validated solutions to support the development of new therapies for clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-18 18:30 |
Accélération du développement en Chine : la coentreprise genOway Shanghai devie…
|
French | 176.7 KB | ||
| 2025-03-27 17:55 |
Résultats annuels 2024 - genOway accélère le déploiement de son plan stratégiqu…
|
French | 223.0 KB | ||
| 2025-01-20 18:00 |
Croissance solide de +10% de l'activité en 2024 à 22,1 M EUR
|
French | 194.7 KB | ||
| 2024-11-04 18:00 |
Lutte contre l'obésité et les maladies métaboliques : les modèles humanisés de …
|
French | 130.1 KB | ||
| 2024-09-23 18:00 |
Résultats semestriels 2024 conformes avec les objectifs du nouveau plan stratég…
|
French | 207.7 KB | ||
| 2024-07-18 18:00 |
Un 1er semestre 2024 en croissance de +15%, de bon augure en pleine mise en oeu…
|
French | 176.4 KB | ||
| 2024-07-04 18:00 |
Bilan semestriel du contrat de liquidité
|
French | 355.0 KB | ||
| 2024-06-25 17:55 |
Solide démarrage du développement de la coentreprise genOway Shanghai en Chine
|
French | 198.0 KB | ||
| 2024-03-28 18:00 |
Organisation d'une visioconférence destinée aux investisseurs individuels
|
French | 128.0 KB | ||
| 2024-03-26 17:45 |
Résultats annuels 2023 : genOway poursuit sur sa lancée avec une croissance de …
|
French | 219.5 KB | ||
| 2024-02-09 11:00 |
genOway fait son entrée au palmarès 2024 des 500 ' Champions de la croissance '
|
French | 129.5 KB | ||
| 2024-01-22 08:00 |
genOway participe à la 1ère édition du Retail Day organisée par Euroland Corpor…
|
French | 125.7 KB | ||
| 2024-01-16 18:05 |
genOway dévoile Route 50+, son nouveau plan stratégique visant à bâtir un leade…
|
French | 198.9 KB | ||
| 2024-01-16 18:00 |
genOway dépasse le seuil des 20 M EUR de chiffre d'affaires en 2023, porté par …
|
French | 176.3 KB | ||
| 2023-11-22 18:00 |
Initiation de la couverture du titre genOway par Euroland Corporate
|
French | 100.2 KB |
Automate Your Workflow. Get a real-time feed of all genOway filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for genOway
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for genOway via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-17 | N/A | Other | Sell | 1,700 | 8,160.00 EUR |
| 2023-12-15 | N/A | Other | Sell | 5,000 | 22,000.00 EUR |
| 2023-11-23 | N/A | Other | Sell | 500 | 2,100.00 EUR |
| 2023-10-23 | N/A | Other | Sell | 100 | 390.00 EUR |
| 2023-09-25 | N/A | Other | Buy | 5,000 | 20,000.00 EUR |
| 2023-05-04 | N/A | Other | Buy | 60,000 | 222,000.00 EUR |
| 2023-05-02 | N/A | Other | Sell | 20,000 | 74,000.00 EUR |
Peer Companies
